Mechanisms underlying the synergistic damage to human squamous cell carcinoma cell line COLO-16 by everolimus and cisplatin: a preliminary study
Ding Min, Xu Song, Li Li, Bi Suyun, Zhou Zhihai, Li Min, Chen Xu, Gu Heng#br#
Department of Dermatology and Venereology, General Hospital, Tianjin Medical University, Tianjin 300052, China(Ding M, Bi SY, Zhou ZH); Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STI, Nanjing 210042, China(Xu S, Li L, Li M, Chen X, Gu H)
National Natural Science Foundation of China(81371755, 81673083, 81773342);Doctoral Fund of Ministry of Education of China(20131106120046); Jiangsu Provincial Special Program of Medical Science(BL2012003); Innovation Research on Critical Diseases(2016ZX320014); CAMS Initiative for Innovative Medicine(2016?12M?1?005)
Ding Min, Xu Song, Li Li, Bi Suyun, Zhou Zhihai, Li Min, Chen Xu, Gu Heng. Mechanisms underlying the synergistic damage to human squamous cell carcinoma cell line COLO-16 by everolimus and cisplatin: a preliminary study[J].Chinese Journal of Dermatology, 2017, 50(10): 739-741.
Xu S, Li L, Li M, et al. Impact on autophagy and ultraviolet B induced responses of treatment with the MTOR inhibitors rapamycin, fverolimus, Torin 1, and pp242 in human keratinocytes[J]. Oxid Med Cell Longev, 2017, 2017: 5930639. DOI: 10.1155/2017/5930639.
[2]
Chen X, Li M, Li L, et al. Trehalose, sucrose and raffinose are novel activators of autophagy in human keratinocytes through an mTOR⁃independent pathway[J]. Sci Rep, 2016, 6: 28423. DOI: 10.1038/srep28423.
[3]
Karayannopoulou G, Euvrard S, Kanitakis J. Differential of p⁃mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTOR inhibitors in organ⁃transplant recipients[J]. Anticancer Res, 2013, 33(9): 3711⁃3714.
[4]
de Fijter JW. Cancer and mTOR inhibitors in transplant recipients[J]. Transplantation, 2017, 101(1): 45⁃55. DOI: 10.1097/TP. 0000000000001447.
Guo H, Zhong Y, Jackson AL, et al. Everolimus exhibits anti⁃tumorigenic activity in obesity⁃induced ovarian cancer[J]. Oncotarget, 2016, 7(15): 20338⁃20356. DOI: 10.18632/oncotarget. 7934.
[7]
Saunders PO, Weiss J, Welschinger R, et al. RAD001 (evero⁃limus) induces dose⁃dependent changes to cell cycle regulation and modifies the cell cycle response to vincristine[J]. Oncogene, 2013, 32(40): 4789⁃4797. DOI: 10.1038/onc.2012.498.
[8]
Yu CC, Hung SK, Liao HF, et al. RAD001 enhances the radio⁃sensitivity of SCC4 oral cancer cells by inducing cell cycle arrest at the G2/M checkpoint[J]. Anticancer Res, 2014, 34(6): 2927⁃2935.
[9]
Selvarajah J, Moumen A, Carroll VA. Role of mTOR⁃Chk1 in enhancing DNA⁃damaging therapy[J]. Cell Cycle, 2015, 14(13): 1989⁃1990. DOI: 10.1080/15384101.2015.1046790.
[10]
Sully K, Akinduro O, Philpott MP, et al. The mTOR inhibitor rapamycin opposes carcinogenic changes to epidermal Akt1/PKBα isoform signaling[J]. Oncogene, 2013, 32(27): 3254⁃3262. DOI: 10.1038/onc.2012.338.